AnaptysBio To Host Investor Event On ANB033 CD122 Antagonist, Featuring Mayo Clinic Expert And Phase 1 Data In Celiac Disease On Oct. 14, 2025 At 4:30 pm ET

Author: Benzinga Newsdesk | September 29, 2025 04:13pm

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14.

The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along with members of the Anaptys management team.

The event will cover:

• ANB033's mechanism of action, an antagonist of the CD122 receptor
• Preclinical data and initial Phase 1a data in healthy volunteers
• Celiac disease (CeD) disease biology and Phase 1b trial design
  
  
  
   

The event will be followed by a Q&A session.

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available following the event.

About ANB033

ANB033, a potentially best-in-class CD122 antagonist, targets CD122, the common beta subunit of IL-15 and IL-2, to reduce NK cells and subsets of cytotoxic CD8+ and CD4+ T cells that are dependent on IL-15 and/or IL-2 for their maintenance, and survival and pathogenic activity. Anaptys has initiated a Phase 1b cohort in an initial indication, celiac disease.

Posted In: ANAB